Evidence map›Paper›PMID 30931172›Full record

ArticleNature biomedical engineering2018

How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation.

John P A Ioannidis, Betty Y S Kim, Alan Trounson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biomedical engineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

John P A IoannidisDepartments of Medicine, Health Research and Policy, and Biomedical Data Science, Stanford University School of Medicine, and Department of Statistics, Stanford University School of Humanities and Sciences, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA. jioannid@stanford.edu.ORCID http://orcid.org/0000-0003-3118-6859
Betty Y S KimDepartments of Neurosurgery, Cancer Biology, and Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL, USA.ORCID http://orcid.org/0000-0001-6890-8355
Alan TrounsonMonash University & Hudson Institute of Medical Research, Clayton, Victoria, Australia.

Funding

Therapeutic modulation of the phagocytosis axis as a novel glioblastoma immunotherapyR01NS104315 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KIM, BETTY · 2018 to 2022
$1.7M
NINDS NIH HHS R01 NS104315
6 · The paper itself

Abstract

The clinical translation of promising products, technologies and interventions from the disciplines of nanomedicine and cell therapy has been slow and inefficient. In part, translation has been hampered by suboptimal research practices that propagate biases and hinder reproducibility. These include the publication of small and underpowered preclinical studies, suboptimal study design (in particular, biased allocation of experimental groups, experimenter bias and lack of necessary controls), the use of uncharacterized or poorly characterized materials, poor understanding of the relevant biology and mechanisms, poor use of statistics, large between-model heterogeneity, absence of replication, lack of interdisciplinarity, poor scientific training in study design and methods, a culture that does not incentivize transparency and sharing, poor or selective reporting, misaligned incentives and rewards, high costs of materials and protocols, and complexity of the developed products, technologies and interventions. In this Perspective, we discuss special manifestations of these problems in nanomedicine and in cell therapy, and describe mitigating strategies. Progress on reducing bias and enhancing reproducibility early on ought to enhance the translational potential of biomedical findings and technologies.

Indexed as

Cell- and Tissue-Based TherapyDrug Evaluation, PreclinicalNanomedicineResearch DesignAdo-Trastuzumab EmtansineAnimalsBreast NeoplasmsDisease Models, AnimalFemaleMaleMaytansineProstatic NeoplasmsReproducibility of ResultsTissue ExtractsTrastuzumabAdo-Trastuzumab EmtansineMaytansinesipuleucel-TTissue ExtractsTrastuzumab

Identifiers

PMID30931172
PMCPMC6436641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.